Kehua Biotech announced that it recently received a medical device registration certificate for a gonococcal nucleic acid detection kit issued by the State Drug Administration. The registration certificate is valid from August 4, 2026 to August 3, 2031. The kit is used to qualitatively test gonococcal nucleic acid in male urethral swabs and female cervical swab samples. The acquisition of a new product registration certificate has enriched the company's product line and had a positive impact on business development, but it is currently impossible to predict the impact on future revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.